FDA grants Priority Review to Roche’s Lunsumio in Lymphoma

 

• Lunsumio® (mosunetuzumab) could be the first CD20xCD3 T-cell engaging bispecific antibody approved by the FDA for the treatment of any type of non-Hodgkin lymphoma
• Application is based on results from the pivotal phase I/II study showing Lunsumio induced high and durable complete response rates in people with follicular lymphoma who received two or more prior therapies
• Lunsumio is a fixed-duration treatment option with the potential to be administered in an outpatient setting

https://www.globenewswire.com/news-release/2022/07/06/2474498/0/en/FDA-grants-Priority-Review-to-Roche-s-Lunsumio-for-people-with-relapsed-or-refractory-follicular-lymphoma.html